nach oben

Journal of Neural Transmission

Erschienen in:

01.12.2012 | Dementias - Short communication

Positive argument for debate in J Neural Transmission: Alzheimer’s disease: are we intervening too late? Yes, by years if not decades

verfasst von: Thomas B. Shea, Ruth Remington

Erschienen in: Journal of Neural Transmission | Ausgabe 12/2012

Einloggen, um Zugang zu erhalten

Abstract

The ongoing debate as to whether we are or are not early enough in treatment for Alzheimer’s disease presents distinct vantage points. Points expressed range from stressing the need for early preventive measures to highlighting the failure of “alternative” therapies, and concluding that we are unfortunately doing all that we can at present. Herein, we stress the worth of nutritional intervention, and review why such studies are often inherently compromised. We conclude that considerable education is needed to advance lifestyle modifications early enough to obtain their optimal effect, and instead of positioning “classical” interventions against “alternative” interventions, the combinations of both may impart maximal benefit. The introduction of novel detection methods at the earliest indications of cognitive impairment may provide a window of opportunity for initiation of preventative approaches.

Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, Raffa RB (2011) Diabetes mellitus and Alzheimer’s disease: shared pathology and treatment? Br J Clin Pharmacol 71:365–376PubMedCrossRef

Ames D (2011) Negative argument for debate with V. O. Emery for J Neural Transmission: Alzheimer’s disease: are we intervening too late? No we are not. Con J Neural Transm 118:1379–1381CrossRef

Andreeva VA, Kesse-Guyot E, Barberger-Gateau P, Fezeu L, Hercberg S, Galan P (2011) Cognitive function after supplementation with B vitamins and long-chain omega-3 fatty acids: ancillary findings from the SU.FOL.OM3 randomized trial. Am J Clin Nutr 94:278–286PubMedCrossRef

Ballard C, Khan Z, Clack H, Corbett A (2011) Nonpharmacological treatment of Alzheimer disease. Can J Psychiatry 56:589–595PubMed

Bragin V, Chemodanova M, Dzhafarova N, Bragin I, Czerniawski JL, Aliev G (2005) Integrated treatment approach improves cognitive function in demented and clinically depressed patients. Am J Alzheimers Dis Other Demen 20:21–26PubMedCrossRef

Chan A, Tchantchou F, Graves V, Rozen R, Shea TB (2008a) Dietary and genetic compromise in folate availability reduces acetylcholine and cognitive performance: critical role of S-adenosylmethionine. J Health Nutr Aging 12:252–261CrossRef

Chan A, Paskavitz J, Remington R, Shea TB (2008b) Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer’s disease: a one-year open-label pilot study with a 16-month extension. Am J Alzheimer Dis Other Dement 23:571–585CrossRef

Chan A, Tchantchou F, Rogers EJ, Shea TB (2009) Dietary deficiency increases presenilin expression, gamma-secretase activity, and Abeta levels: potentiation by ApoE genotype and alleviation by S-adenosyl methionine. J Neurochem 110:831–836PubMedCrossRef

Chan A, Lepore A, Kotoya E, Zemianek J, Remington R, Shea TB (2010) Efficacy of a vitamin/nutriceutical formulation on cognitive speed and recall in adults with no known or suspected dementia. J Nutri Health Aging 14:224–230CrossRef

Connelly PJ, Prentice NP, Cousland G, Bonham J (2008) A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer’s disease. Int J Geriatr Psychiatry 23:155–160PubMedCrossRef

Cornelli U (2010) Treatment of Alzheimer’s disease with a cholinesterase inhibitor combined with antioxidants. Neurodegener Dis 7:193–202PubMedCrossRef

Daviglus ML, Plassman BL, Pirzada A, Bell CC, Bowen PE, Burke JR, Connolly ES Jr, Dunbar-Jacob JM, Granieri EC, McGarry K, Patel D, Trevisan M, Williams JW Jr (2011) Risk factors and preventive interventions for Alzheimer disease: state of the science. Arch Neurol 68:1185–1190PubMedCrossRef

de Sousa OL, Amaral TF (2012) Three-week nutritional supplementation effect on long-term nutritional status of patients with mild Alzheimer disease. Alzheimer Dis Assoc Disord 26:119–123

Dhitavat S, Ortiz D, Rogers E, Rivera E, Shea TB (2005) Folate, vitamin E and acetyl-l-carnitine provide synergistic protection against oxidative stress resulting from exposure of human neuroblastoma cells to amyloid beta. Brain Res 1061:114–117PubMedCrossRef

Dubois B, Feldman HH, Jacova C, Dekosy ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O’Brien K, Paquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS—ADRDA criteria. Lancet Neurol 6:734–746PubMedCrossRef

Durga J, van Boxtel MP, Schouten EG et al (2007) Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet 369:208–216PubMedCrossRef

Ellison M, Thomas J, Patterson A (2004) A critical evaluation of the relationship between serum vitamin B12, folate and total homocysteine with cognitive impairment in the elderly. J Ji Mitr Doetet 17:371–383

Emery VO (2011) Alzheimer disease: are we intervening too late? Pro J Neural Transm 118:1361–1378CrossRef

Fuso A, Cavallaro RA, Zampelli A, D’Anselmi F, Piscopo P, Confaloni A, Scarpa S (2007) Gamma-secretase is differentially modulated by alterations of homocysteine cycle in neuroblastoma and glioblastoma cells. J Alzheimer Dis 11:275–290

Fuso A, Nicolia V, Ricceri L, Cavallaro RA, Isopi E, Mangia F, Fiorenza MT, Scarpa S (2012) S-adenosylmethionine reduces the progress of the Alzheimer-like features induced by B-vitamin deficiency in mice. Neurobiol Aging 33:1482e1–1482e16

Kang JH, Cook N, Manson J, Buring JE, Grodstein F (2006) A randomized trial of vitamin E supplementation and cognitive function in women. Arch Intern Med 166:2462–2468PubMedCrossRef

Kang JH, Cook N, Manson J, Buring JE, Albert CM, Grodstein F (2008) A trial of B vitamins and cognitive function among women at high risk of cardiovascular disease. Am J Clin Nutr 88:1602–1610PubMedCrossRef

Kroner Z (2009) The relationship between Alzheimer’s disease and diabetes: type 3 diabetes? Altern Med Rev 14:373–379PubMed

LaMonte MJ, Blair SN, Church TS (2005) Physical activity and diabetes prevention. J Appl Physiol 99:1205–1213PubMedCrossRef

Lee S, Lemere CA, Frost JL, Shea TB (2011) Dietary supplementation with S-adenosyl methionine delayed amyloid-β and tau pathology in 3xTg-AD mice. J Alzheimers Dis 28:423–431

Lopez OL, McDade E, Riverol M, Becker JT (2011) Evolution of the diagnostic criteria for degenerative and cognitive disorders. Curr Opin Neurol 24:532–541PubMedCrossRef

Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G, Bava A (2004) Vitamin B12 and folate depletion in cognition: a review. Neurol India 52:310–318PubMed

Morris MC, Tangney CC (2011) A potential design flaw of randomized trials of vitamin supplements. JAMA 305:1348–1349PubMedCrossRef

Okosun IS, Davis-Smith M, Seale JP (2012) Awareness of diabetes risks is associated with healthy lifestyle behavior in diabetes free American adults: evidence from a nationally representative sample. Prim Care Diabetes 6:87–94

Panza F, Frisardi V, Capurso C, D’Introno A, Colacicco AM, Vendemiale G, Capurso A, Solfrizzi V (2009) Possible role of S-adenosylmethionine, S-adenosylhomocysteine, and polyunsaturated fatty acids in predementia syndromes and Alzheimer’s disease. J Alzheimers Dis 16:467–470PubMed

Planel E, Miyasaka T, Launey T, Chui DH, Tanemura K, Sato S, Murayama O, Ishiguro K, Tatebayashi Y, Takashima A (2004) Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer’s disease. J Neurosci 24:2401–2411PubMedCrossRef

Qi L, Hu FB, Hu G (2008) Genes, environment, and interactions in prevention of type 2 diabetes: a focus on physical activity and lifestyle changes. Curr Mol Med 8:519–532PubMedCrossRef

Remington R, Chan A, Shea TB (2009) Efficacy of a vitamin/nutriceutical formulation for moderate to late-stage Alzheimer’s disease: a placebo-controlled pilot study. Am J Alzheimer Dis Other Dement 24:27–33CrossRef

Rivière S, Gillette-Guyonnet S, Voisin T, Reynish E, Andrieu S, Lauque S, Salva A, Frisoni G, Nourhashemi F, Micas M, Vellas B (2001) A nutritional education program could prevent weight loss and slow cognitive decline in Alzheimer’s disease. J Nutr Health Aging 5:295–299PubMed

Sebastian RS, Cleveland LE, Goldman JD, Moshfegh AJ (2007) Older adults who use vitamin/mineral supplements differ from nonusers in nutrient intake adequacy and dietary attitudes. J Am Diet Assoc 107:1322–1332PubMedCrossRef

Shea TB, Chan A (2008) S-adenosyl methionine: a natural therapeutic agent effective against multiple hallmarks and risk factors associated with Alzheimer’s disease. J Alzheimer Dis 13:67–70

Solfrizzi V, Frisardi V, Seripa D, Logroscino G, Imbimbo BP, D’Onofrio G, Addante F, Sancarlo D, Cascavilla L, Pilotto A, Panza F (2011a) Mediterranean diet in predementia and dementia syndromes. Curr Alzheimer Res 8:520–542PubMedCrossRef

Solfrizzi V, Panza F, Frisardi V, Seripa D, Logroscino G, Imbimbo BP, Pilotto A (2011b) Diet and Alzheimer’s disease risk factors or prevention: the current evidence. Expert Rev Neurother 11:677–708PubMedCrossRef

Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:280–292PubMedCrossRef

Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease—is this type 3 diabetes? J Alzheimers Dis 7:63–80

Sun Y, Lu CJ, Chien KL, Chen ST, Chen RC (2007) Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer’s disease: a 26-week, randomized, double-blind, placebo-controlled study in Taiwanese patients. Clin Ther 29:2204–2214PubMedCrossRef

Vellas B, Lauque S, Gillette-Guyonnet S, Andrieu S, Cortes F, Nourhashémi F, Cantet C, Ousset PJ, Grandjean H, REAL.FR Group (2005) Impact of nutritional status on the evolution of Alzheimer’s disease and on response to acetylcholinesterase inhibitor treatment. J Nutr Health Aging 9:75–80PubMed

Werder SF (2010) Cobalamin deficiency, hyperhomocysteinemia, and dementia. Neuropsychiatr Dis Treat 6:159–195PubMedCrossRef

Wollen KA (2010) Alzheimer’s disease: the pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners Alt. Med Rev 15:226–244

Zawia NH, Lahiri DK, Cardozo-Pelaez (2009) Epigenetics, oxidative stress and Alzheimer’s disease. Free Rad Biol Med 46:1241–1249

Zhu X, Raina AK, Lee HG, Casadesus G, Smith MA, Perry G (2004) Oxidative stress signaling in Alzheimer’s disease. Brain Res 1000:32–39PubMedCrossRef

Titel: Positive argument for debate in J Neural Transmission: Alzheimer’s disease: are we intervening too late? Yes, by years if not decades
verfasst von: Thomas B. Shea
Ruth Remington
Publikationsdatum: 01.12.2012
Verlag: Springer Vienna
Erschienen in: Journal of Neural Transmission / Ausgabe 12/2012
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-012-0849-0

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2012

Auditory processing in remitted major depression: a long-term follow-up investigation using 3T-fMRI

Iron accumulation in Parkinson’s disease

Swainsonine as a lysosomal toxin affects dopaminergic neurons

Nigral Tau pathology and striatal amyloid-β deposition does not correlate with striatal dopamine deficit in Alzheimer’s disease

Different molecular pathologies result in similar spatial patterns of cellular inclusions in neurodegenerative disease: a comparative study of eight disorders